University College Cardiff Consultants Limited

Lewis Pennicott

Paul John Beswick

Simon Ward

Tristan Reuillon

Irina Chuckowree

Carolina Villalonga-Barber

Roderick Alan Porter

The invention provides compounds of the formula (I): (I) wherein A, A, R, R, B, B, X, X, n, a and b are as defined are defined in the specification, to pharmaceutical compositions comprising the compounds and the compounds for use as medicaments. The compounds potentiate AMPA receptor function and are expected to be useful in the treatment of central nervous system disorders, for example in the treatment of depressive disorders, mood disorders and cognitive dysfunction associated with neuropsychiatric disorders such as schizophrenia.

Compounds that modulates AMPA receptor function

The invention provides compounds of the formula (I): (I) wherein A, A, R, R, B, B, X, X, n, a and b are as defined are defined in the specification, to pharmaceutical compositions comprising the compounds and the compounds for use as medicaments. The compounds potentiate AMPA receptor function and are expected to be useful in the treatment of central nervous system disorders, for example in the treatment of depressive disorders, mood disorders and cognitive dysfunction associated with neuropsychiatric disorders such as schizophrenia. 

The invention provides compounds of the formula (I): wherein Rand Rare defined in the specification, to pharmaceutical compositions comprising the compounds and the compounds for use as medicaments. The compounds potentiate AMPA receptor function and are expected to be useful in the treatment of central nervous system disorders, for example in the treatment of depressive disorders, mood disorders and cognitive dysfunction associated with neuropsychiatric disorders such as schizophrenia. 

Growing community of inventors

Falmer, United Kingdom

Lewis Pennicott